Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q2 EPS of $0.31, $0.12 better than the analyst estimate of $0.19. Revenue for the quarter came in at $98.22 million versus the consensus estimate of $92.14 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.